Medical Cannabis Advocacy in the Caribbean During the 1990s

Context: ganja was illegal everywhere in the region

Entering the 1990s, every Anglophone Caribbean state criminalized cannabis under some version of a Dangerous Drugs Act, most tracing back to colonial-era statutes influenced by the 1961 UN Single Convention on Narcotic Drugs ^[1]. Jamaica's Dangerous Drugs Act of 1948 (as amended) remained the operative framework, and possession, cultivation, and use were all offenses ^[2]. The United States, through the annual State Department International Narcotics Control Strategy Report and certification process, actively pressured Caribbean governments to maintain enforcement and eradication programs during the decade ^[3]. This is the environment any 1990s 'medical cannabis advocacy' had to operate inside — there was no legal medical channel to reform, only criminal statutes to challenge.

Rastafari religious-freedom cases, not medical claims

The most visible 1990s advocacy came from Rastafari communities, but it was framed primarily as religious freedom, not medical use. In Guyana, the case of Chandra v. State and related prosecutions kept sacramental use in the courts. In the United States, the landmark Employment Division v. Smith (1990) shaped how Caribbean-diaspora Rastafari religious-use defenses were argued, generally unsuccessfully ^[4]. Regionally, Rastafari organizations such as the Rastafari Centralization Organisation and the Nyabinghi Order petitioned governments for sacramental exemption throughout the decade, citing the herb's use in reasoning sessions and healing rituals Strong evidence ^[5]. Medical claims — that ganja helped with glaucoma, asthma, or 'nerves' — appeared in these petitions, but they were secondary to the religious argument and were rarely backed by clinical data at the time Weak / limited.

The UWI research thread

A small but influential body of research at the University of the West Indies (UWI), Mona campus, provided the closest thing to a medical-evidence base for Caribbean advocacy. The foundational work predates the 1990s: Melanie Dreher's ethnographic study Working Men and Ganja (1982) documented daily cannabis use patterns in rural Jamaica ^[6], and Vera Rubin and Lambros Comitas's Ganja in Jamaica (1975) presented the first controlled clinical study of chronic users ^[7]. In the 1990s, Dreher and colleagues published a follow-up study on neonatal outcomes among prenatally exposed Jamaican infants that found no significant developmental deficits at one month — a finding still frequently cited, and frequently overstated, in advocacy contexts ^[8] Weak / limited. Manley West and Albert Lockhart's development of Canasol, a cannabis-derived eye-drop for glaucoma approved for pharmacy sale in Jamaica in the late 1980s, was a genuine 1990s talking point for local advocates ^[9] Strong evidence. Canasol is the clearest example of an actual medical cannabis product in the region during this period.

HIV/AIDS harm reduction, quietly

The Caribbean HIV/AIDS epidemic peaked in the 1990s, and by decade's end the region had the second-highest adult HIV prevalence in the world after sub-Saharan Africa ^[10]. In North America and Europe, HIV/AIDS patient activism was a major driver of medical cannabis reform (California's Proposition 215 in 1996 being the canonical example). In the Caribbean, similar patient-level use for wasting and appetite loss occurred but was rarely organized into public advocacy — the combination of HIV stigma, drug-war politics, and cannabis criminalization made public campaigning risky Anecdote. This is an area where the historical record is thin, and claims about organized 1990s Caribbean AIDS-cannabis coalitions should be treated skeptically absent primary documentation.

The Chevannes Commission: end of the decade, start of the shift

The clearest institutional outcome of 1990s advocacy came in 2000, when the Jamaican government appointed the National Commission on Ganja, chaired by UWI sociologist Barry Chevannes. Its 2001 report recommended decriminalizing small-quantity personal use and permitting Rastafari sacramental use, and it explicitly cited both the UWI research tradition and Rastafari petitions accumulated over the preceding decade ^[11]. The recommendations were not implemented in Jamaica until the Dangerous Drugs (Amendment) Act of 2015 — fifteen years later. The Commission is the best documentary evidence that 1990s Caribbean advocacy existed as a coherent movement, even if its wins were deferred Strong evidence.

Myths worth flagging

Several claims about the 1990s Caribbean movement circulate online and deserve correction:

• 'Jamaica nearly legalized medical cannabis in the 1990s.' No. There was no serious legislative proposal until after the 2001 Chevannes report, and medical framework legislation didn't pass until 2015 Disputed.
• 'Rastafari won religious-use exemptions in the 1990s.' No Anglophone Caribbean state granted a sacramental exemption during the decade. Jamaica's limited sacramental provision came in 2015 ^[11].
• 'Bob Marley's estate funded 1990s medical cannabis research.' No verifiable primary source supports this; the commercial Marley-branded cannabis ventures date to the 2010s No data.
• 'The Dreher infant study proved prenatal cannabis is safe.' The study had a small sample, short follow-up, and confounds the author herself acknowledged; it is one data point, not a settled question ^[8] Weak / limited.

Sources

How this page was made